Drug Resistance in Leishmania Parasites 2018
DOI: 10.1007/978-3-319-74186-4_4
|View full text |Cite
|
Sign up to set email alerts
|

Epidemiology of Leishmaniasis in the Time of Drug Resistance (the Miltefosine Era)

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1

Citation Types

0
4
0

Year Published

2019
2019
2024
2024

Publication Types

Select...
5
1

Relationship

2
4

Authors

Journals

citations
Cited by 6 publications
(4 citation statements)
references
References 100 publications
0
4
0
Order By: Relevance
“…Leishmania cause a broad spectrum of clinical presentations, the most severe being visceral leishmaniasis (VL) which annually affects up to 90,000 new individuals [1] and has a 10% mortality rate [2]. Ongoing control programs, like the one running in the Indian subcontinent (ISC) [3] could be challenged by several factors, including drug resistance [4,5] and emergence of new parasite variants [6,7]. More than ever, close surveillance is required to avoid new epidemics, including molecular tracking of the etiological agent.…”
Section: Introductionmentioning
confidence: 99%
“…Leishmania cause a broad spectrum of clinical presentations, the most severe being visceral leishmaniasis (VL) which annually affects up to 90,000 new individuals [1] and has a 10% mortality rate [2]. Ongoing control programs, like the one running in the Indian subcontinent (ISC) [3] could be challenged by several factors, including drug resistance [4,5] and emergence of new parasite variants [6,7]. More than ever, close surveillance is required to avoid new epidemics, including molecular tracking of the etiological agent.…”
Section: Introductionmentioning
confidence: 99%
“…It was synthesized according to the general procedure described above from 11bromoundecan-1-ol (6). Colourless oil [50]; yield: 3.1 g, 97%; 1 H-NMR (300 MHz, CDCl 3 ) δ 3.47 (t, J = 6.72 Hz, 2H), 3.14 (t, J = 6.72 Hz, 2H), 1.50-1.41 (m, 4H), 1.17 (s, 14H); 13…”
Section: -Azidoundecan-1-ol (9)mentioning
confidence: 99%
“…Unfortunately, the standard treatment of Leishmaniasis depends on poorly tolerated drugs with high toxicity. In addition, a major problem encountered in clinical practice is the increased chemoresistance of the parasite [ 6 ].…”
Section: Introductionmentioning
confidence: 99%
“…In some regions, mainly where resistance has developed, miltefosine, paramycin, and liposomal amphotericin B are gradually replacing the antimonials ( 9 , 10 ). Nowadays, due to some factors such as side effects, drug resistance, excessive and economic costs of medical services, lack of easy access to these medications in some areas, researchers are looking for effective alternative drugs to reduce the side effects of CL treatment ( 11 , 12 , 13 ). One way to do so is the use of safe plant extracts in the treatment of the disease.…”
Section: Introductionmentioning
confidence: 99%